Skip to content
sellWeak cluster of 610b5-1 plan

Adeoye Y Olukotun sold $677k of ARWR

director at ARROWHEAD PHARMACEUTICALS, INC.. 10,000 shares at an average of $67.66, traded Dec 19, 2025, filed Dec 23, 2025.

Warning score
35
Value
$677k
10,000 shares
Holdings after
33,600
-23% from before
From 52-week low
+582%
low $9.99, close $68.16
From 52-week high
-4%
high $70.82, as of Dec 19, 2025

Score components

  • Role
    Director
    +15
  • Trade size
    $677k at market
    +20
  • Share of holdings sold
    Sold 23% of holdings
    +5
  • Cluster
    6 insiders selling within 14 days
    +15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

ARWROct 9, 2026 · close 62.75
Since filing Dec 23, 2025: -10.1%SPY +14.1% · excess -24.2%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001242615-25-000006, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Dec 19, 2025SOpen-market sale
Common Stock10b5-1
-3,090$66.70$206k40,510Dec 23, 2025
Dec 19, 2025SOpen-market sale
Common Stock10b5-1
-6,083$68.04$414k34,427Dec 23, 2025
Dec 19, 2025SOpen-market sale
Common Stock10b5-1
-827$68.48$57k33,600Dec 23, 2025

Related signals

Other insiders at ARROWHEAD PHARMACEUTICALS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
8Weak
ARWRsell10b5-1
ARROWHEAD PHARMACEUTICALS, INC.
Hongbo Lu
director
$228k
2,970 shares
-5%
34Weak
ARWRsell 210b5-1
ARROWHEAD PHARMACEUTICALS, INC.
Daniel Joseph Apel
Chief Financial Officer
$934k
13,095 shares
-7%
25Weak
ARWRsell 210b5-1
ARROWHEAD PHARMACEUTICALS, INC.
James C Hamilton
Chief Medical Officer
$750k
10,000 shares
-4%
15Weak
ARWRsell10b5-1
ARROWHEAD PHARMACEUTICALS, INC.
James C Hamilton
Chief Medical Officer
$642k
10,000 shares
-4%
43Moderate
ARWRsell 710b5-1
ARROWHEAD PHARMACEUTICALS, INC.
Christopher Richard Anzalone
Chief Executive Officer
$872k
13,187 shares
-0%
40Moderate
ARWRsell 410b5-1
ARROWHEAD PHARMACEUTICALS, INC.
Patrick O'Brien
COO
$3.1M
49,493 shares
-9%
40Moderate
ARWRsell 410b5-1
ARROWHEAD PHARMACEUTICALS, INC.
James C Hamilton
Chief Medical Officer
$2.5M
40,164 shares
-19%
30Weak
ARWRsell 710b5-1
ARROWHEAD PHARMACEUTICALS, INC.
Christopher Richard Anzalone
Chief Executive Officer
$3.6M
51,726 shares
-1%
28Weak
ARWRsell 710b5-1
ARROWHEAD PHARMACEUTICALS, INC.
Mauro Ferrari
director
$527k
7,530 shares
-10%
45Moderate
ARWRsell 610b5-1
ARROWHEAD PHARMACEUTICALS, INC.
Christopher Richard Anzalone
Chief Executive Officer
$1.8M
26,031 shares
-1%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Adeoye Y Olukotun sold $677k of ARWR | InsiderTell